September 2011 | Oncology & Biotech News

October 18, 2011

The controversy over the breast cancer indication for Avastin culminated in June when the ODAC voted after an unusual and emotional 2-day hearing to uphold a prior recommendation to withdraw the label indication.

October 14, 2011

For more than 75 years, the cancer programs of Duke University Medical Center in Durham, North Carolina, have been at the forefront of research and patient care.

October 10, 2011

During the past 40 years, the concept of thwarting a tumor by attacking its blood supply has become a central thrust of cancer research, a strategy that reached a milestone with the approval of bevacizumab in 2004.

October 06, 2011

Despite controversy over its breast cancer approval status, bevacizumab (Avastin) remains at center stage when it comes to antiangiogenic therapies for the disease.

October 06, 2011

Leading breast cancer researcher Joyce A. O'Shaughnessy, MD, developed and chaired the 10th International Congress on the Future of Breast Cancer, a 4-day interactive program.

October 05, 2011

Professor of Surgery and Consultant Surgeon at the University of Edinburgh; and Clinical Director of the Edinburgh Breast Unit at the Western General Hospital in Edinburgh, Scotland.

October 04, 2011

Dendreon estimates that only about 25% of eligible prescribing physicians were aware that Medicare had decided to cover Provenge for its on-label use of treating prostate cancer.

October 03, 2011

BIND, based in Cambridge, Massachusetts, was founded in 2007 by two researchers with experience in the field of targeted nanoparticles.

September 30, 2011

Through the success of Revlimid and other drugs, Celgene has become a respected and powerful player in the biopharmaceutical industry in recent years.

September 29, 2011

Temporary ovarian suppression using triptorelin may decrease the rate of early menopause in premenopausal women with early-stage breast cancer undergoing adjuvant or neoadjuvant chemotherapy.

September 28, 2011

British investigators are reporting that taller women have a higher risk of cancer, and that the link between height and cancer risk exists for most types of cancer.

September 28, 2011

The investigational oral agent talactoferrin alfa reduces the risk of death in patients being treated in the intensive care unit for severe sepsis.

September 27, 2011

Brentuximab vedotin showed very positive results in lymphoma patients in several early trials, prompting the FDA's Oncologic Drugs Advisory Committee to unanimously recommend accelerated approval for the drug.

September 26, 2011

Weekly high-dose vitamin D supplementation improves joint and muscle pain related to anastrozole therapy in breast cancer patients with low vitamin D levels.

September 23, 2011

In vitro cell manipulation has unleashed the therapeutic potential of human cells.